Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Vous n'êtes pas connecté
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Eli Lilly stock boasts both defensive and growth characteristics
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
DLTR's Q2 results are likely to reflect the impacts of soft demand for discretionary items, elevated shrink, an unfavorable mix and higher SG&A...
The 2024 Q2 earnings season is slowly grinding to a halt, with the majority of S&P 500 companies already delivering quarterly results. And during...
DBI's Q2 results reflect lower turnover across the U.S. retail segment. It continues to focus on strategic investments and brand expansion to drive...
SIG's Q2 same-store sales dip due to digital banner issues. The company is likely to experience tailwinds due to its growth initiatives.
Construction projects of major companies such as Intel, Diageo and Eli Lilly will be impacted.
PLAY's second-quarter fiscal 2024 performance is likely to be hurt by dismal traffic and high costs.